FDA Panel to Review Medtronic's (MDT) Bryan Cervical Disc System
Tweet Send to a FriendGet Alerts MDT Hot Sheet
Price: $51.33 -0.25%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 2.7%
EPS Growth %: +11.1%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 2.7%
EPS Growth %: +11.1%
Trade MDT Now!
Medtronic, Inc. (NYSE: MDT) recently announced the Bryan Cervical Disc System will be reviewed by the U.S. Food and Drug Administration's (FDA) Orthopedic and Rehabilitation Devices advisory panel on July 17, 2007.
William Hawkins, president and chief operating officer, made the announcement during Medtronic's fourth quarter earnings conference call on Tuesday, May 22. If the panel votes to recommend approval, the FDA will consider this vote when deciding on full approval. The Bryan Cervical Disc System is the second disc arthroplasty system for the cervical spine to be reviewed by an FDA panel. The first, Medtronic's Prestige Cervical Disc, is currently under evaluation by the FDA with expected approval later this summer.
The Bryan Cervical Disc is designed to alleviate pain and preserve motion and flexibility while replacing a diseased disc that is removed from a patient's cervical spine.
William Hawkins, president and chief operating officer, made the announcement during Medtronic's fourth quarter earnings conference call on Tuesday, May 22. If the panel votes to recommend approval, the FDA will consider this vote when deciding on full approval. The Bryan Cervical Disc System is the second disc arthroplasty system for the cervical spine to be reviewed by an FDA panel. The first, Medtronic's Prestige Cervical Disc, is currently under evaluation by the FDA with expected approval later this summer.
The Bryan Cervical Disc is designed to alleviate pain and preserve motion and flexibility while replacing a diseased disc that is removed from a patient's cervical spine.
You May Also Be Interested In
- Medtronic (MDT) Receives CE Mark for Export Advance Catheter
- Janssen Pharma (JNJ) Plans Slew of Filing, Extension Submissions by FY17
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
